NCT01591122View on ClinicalTrials.gov

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

March 27, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Placebo and prednisone

Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.

DRUG

Abiraterone acetate and prednisone

Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily

Trial Locations (22)

Unknown

Beijing

Chengdu

Chongqing

Guangzhou

Hangzhou

Jinan

Nanjing

Shanghai

Tianjin

Wuhan

Kuala Lumpur

Arkhangelsk

Moscow

Pyatigorsk

Rostov-on-Don

Saint Petersburg

Sochi

Stavropol

Ufa

Yekaterinburg

Yoshkar-Ola

Bangkok

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01591122 - Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter